Retrospective Review on Uterovaginal Anomalies
Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 13, 2024
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the surgical outcomes of women who have had surgery for conditions related to uterovaginal anomalies, which are abnormalities affecting the uterus and vagina. Researchers will review the medical records of these patients from the Prince of Wales Hospital, focusing on the results of their surgeries to gather important data for analysis.
To be eligible for this study, participants must be female and have been diagnosed with a uterovaginal anomaly while receiving care at the hospital since the year 2000. There are no specific exclusions, meaning anyone meeting the inclusion criteria can participate. If you or someone you know qualifies, you can expect that your past medical records will be examined to help improve understanding of these conditions and the effectiveness of surgical treatments. This study is currently recruiting participants, so it's a great opportunity to contribute to valuable research in this area.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • All patients who attended the Prince of Wales Hospital with the diagnosis of uterovaginal anomaly since 2000
- Exclusion Criteria:
- • Nil
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported